Evidence map›Paper›PMID 28405738›Full record

ArticleInternational journal of colorectal disease2017

Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer.

Paweł Krawczyk, Tomasz Powrózek, Tomasz Olesiński, Adam Dmitruk, Joanna Dziwota, Dariusz Kowalski, Janusz Milanowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Novel Diagnostic Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paweł KrawczykDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland. krapa@poczta.onet.pl.
Tomasz PowrózekDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
Tomasz OlesińskiDepartment of Oncological Gastroenterology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, WK Roentgen 5, 02-781, Warsaw, Poland.
Adam DmitrukDepartment of Oncological Gastroenterology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, WK Roentgen 5, 02-781, Warsaw, Poland.
Joanna DziwotaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.
Dariusz KowalskiDepartment of Lung and Chest Tumor, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in Warsaw, WK Roentgen 5, 02-781, Warsaw, Poland.
Janusz MilanowskiDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-954, Lublin, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExamination of the entire colon by colonoscopy remains the golden standard for screening of colorectal cancer (CRC). However, patients are reluctant to perform invasive colonoscopies because of interference with their intimacy. Therefore, the potential use of non-invasive analysis of microRNAs expression in liquid biopsy as a novel biomarker for early CRC has investigated in several studies. In this study, we analyzed the expression of two novel microRNAs: miR-506 and miR-4316, which have never been examined in CRC.

methodsPlasma samples were collected from 56 patients (median age of 68 years) with operable colorectal cancer and from 70 healthy individuals (median age of 59 years). Expression of plasma microRNAs was evaluated by quantitative reverse transcription polymerase chain reaction using Eco real-time PCR device (Illumina, USA).

resultsWe found a significant elevated expression of both examined microRNAs in early CRC patients when compared to those in healthy individuals (p = 0.0054 for miR-506 and p = 0.0025 for miR-4316). The expression of miR-506 and miR-4316 did not depend on gender, age, disease stage, and tumor localization of CRC patients. ROC curve analysis showed that both examined microRNAs could differentiate early stage colorectal cancer from healthy individuals with 76.8% specificity and 60.7% sensitivity for miR-506 analysis and 76.8% specificity and 75% specificity for miR-4316 analysis.

conclusionOur study revealed that elevated expression of miR-506 and miR-4316 in peripheral blood were potential molecular markers for early colorectal cancer.

Indexed as

AgedColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsROC CurveMicroRNAsMIRN4316 microRNA, humanMIRN506 microRNA, humanColorectal cancerEarly diagnosis and preventionLiquid biopsymicroRNAs

Identifiers

PMID28405738
PMCPMC5486640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.